David Daly - Foundation Medicine Chief Commercial Officer

Executive

Mr. David J. Daly was Chief Commercial Officer of the Company. Prior to joining Foundation Medicine, from March 2014 to December 2014 he served as vice president, commercial operations for the Anatomic Pathology Division at Thermo Fisher Scientific, a life sciences research and diagnostics company. Prior to its acquisition by Thermo Fisher Scientific, from June 2012 to March 2014 Mr. Daly served as head of oncology, medical sciences at Life Technologies, a commercial clinical diagnostics company. Prior to Life Technologies, from May 2009 to June 2012, Mr. Daly served as chief commercial officer for Clarient, an anatomic pathology company, that was later acquired by GE Healthcare. Mr. Daly also served as vice president of commercial operations at Clarient from February 2008 to May 2009. Mr. Daly was also vice president of sales and marketing from February 2006 to February 2008 and vice president of sales from February 2005 to February 2006 at Clarient. In addition, Mr. Daly also served in various sales and marketing leadership roles in molecular diagnostics, hematology, and laboratory automation with Roche Diagnostics and Abbott Laboratories.
Age 53
Phone617 418-2200
Webwww.foundationmedicine.com
Daly holds a Bachelor of Arts degree and a Master’s degree in economics from the University of California, Irvine and Santa Barbara, respectively.

Foundation Medicine Management Efficiency

Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Kara KelchnerStrongBassett Furniture Industries
N/A
Michael MeansDouglas Emmett
63
Christopher GuldenSL Green Realty
N/A
Arista JoynerBoston Properties
N/A
Neil KessnerSL Green Realty
N/A
Darlan MonterisiPlaytika Holding Corp
N/A
Maggie HuiSL Green Realty
60
Michael EsqPlaytika Holding Corp
53
Philippe DeschenesBRP Inc
N/A
Allan GoladDouglas Emmett
69
Steven DurelsSL Green Realty
65
Helen HanBoston Properties
N/A
Richard CurrentiSL Green Realty
N/A
Theodore GuthDouglas Emmett
69
Katie MendoleraHaverty Furniture Companies
41
Kelly FladgerHaverty Furniture Companies
54
Sebastien MartelBRP Inc
52
Stephane BilodeauBRP Inc
57
Kevin CrummyDouglas Emmett
58
Edward WhiteBassett Furniture Industries
N/A
Gili BrudnoPlaytika Holding Corp
50
Foundation Medicine, Inc. provides various molecular information products in the United States. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc. Foundation Medicine operates under Diagnostics Research classification in USA and traded on NASDAQ. It employs 662 people. Foundation Medicine (FMI) is traded on NASDAQ Exchange in USA and employs 662 people.

Management Performance

Foundation Medicine Leadership Team

Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
Daniel Day, Director
Michael Varney, Director
Krishna Yeshwant, Independent Director
David Daly, Chief Commercial Officer
David Schenkein, Independent Director
Melanie Nallicheri, Chief business Officer and head of Biopharma
Alexis Borisy, Chairman of the Board, Co-Founder
Steven Kafka, Pres and COO
Evan Jones, Independent Director
Vincent Miller, Chief Medical Officer
Konstantin Fiedler, COO
Michael Pellini, President CEO, Director
Robert Hesslein, Senior Vice President General Counsel
Sandra Horning, Director
Michael Doherty, Head of Product Development
Jason Ryan, CFO
Michael Dougherty, Director
Tom Civik, Chief Commercial Officer
Troy Cox, CEO, Director
Thomas Civik, Chief Commercial Officer

Foundation Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Consideration for investing in Foundation Stock

If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data